Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough Control

Trevi Therapeutics is facing challenges in developing a non-opioid treatment for cough control due to regulatory and market pressures. Investors are cautious about the company's ability to navigate the complexities of opioid regulation while ensuring effective treatment options. Additionally, the public health implications of opioid addiction may affect market acceptance of any new products. The company is exploring alternative formulations, but skepticism remains among investors regarding commercial viability. As a result, the stock's volatility is likely to increase as these developments unfold.